World Bispecific Summit Europe BIO on July 07-09, 2026 in London, United Kingdom

The bispecific and multispecific antibody field is advancing rapidly, fuelled by strong clinical readouts, growing biopharma investment, and increasingly sophisticated antibody designs. As programs evolve beyond first-generation bispecifics toward trispecific and multispecific strategies, the industry is sharpening its focus on improving efficacy while expanding the therapeutic window through improved safety and toxicity profiles.

With an increasing number of bispecifics progressing toward the clinic, the inaugural World Bispecific Summit Europe brings Europe's bispecific leaders together for the first time, building on the proven success of the World Bispecific Summit US.

This industry-led forum delivers deep technical discussions and case studies spanning novel antibody formats, next-generation TCEs, and bispecific ADCs, accelerating bispecifics from bench to clinic through conditional activation strategies, co-stimulation, and translational insights.

With clinical momentum accelerating and unresolved challenges still to solve, now is the time to connect, collaborate, and shape the future of bispecific therapies. Join a high-calibre community in London, July 2026, and be part of the next wave of precision-driven care.

URLs:

Website: https://go.evvnt.com/3495668-0?pid=10008

Tickets: https://go.evvnt.com/3495668-2?pid=10008

Brochure: https://go.evvnt.com/3495668-3?pid=10008

Prices:

Conference Only - Service Provider: GBP 3199.00,

Conference + Workshop Day - Service Provider: GBP 4497.00,

Conference Day Only - Academic Pricing: GBP 2299.00,

Conference + Workshop Day - Academic Pricing: GBP 3197.00,

Conference Only - Drug Developer: GBP 2699.00,

Conference + Workshop Day - Drug Developer: GBP 3797.00

Speakers: David Cole, Head of Research, Accession Therapeutics, Asis Palazon, Chief Executive Officer, Adaptam Therapeutics, Petra Lutterbuese, Principal Scientist, Amgen, Catherine Huntington, Associate Director, AstraZeneca, Christopher Lloyd, Director, Biologics Engineering, AstraZeneca, Simon Plyte, Chief Scientific Officer, Biomunex Pharmaceuticals, James Legg, Chief Scientific Officer, Cytospire Therapeutics Ltd, Tobias Schmidt, Senior Vice President, Head of Discovery, DISCO Pharmaceuticals, Arnaud Goepfert, Vice President, Biologics Engineering, Ennovate Pharma, Kristel Kemper, Director, Team Lead Early Translational Medicine and Research Projects, Genmab, Annelise Vuidepot, Chief Science and Technology Officer, Immunocore, Angus Sinclair, Chief Scientific Officer, LabGenius Therapeutics, Vanessa Buatois, Discovery Program Leader, Light Chain Bioscience / Novimmune, Martin Steegmaier, Chief Scientific Officer, Molecular Partners AG, David Granger, Vice President, Research and Development, NovalGen, Matthew Lambert, Senior Director, Pfizer, Abdullah Elsayed, Group Leader, R and D, Philochem, Andreas Hollenstein, Senior Principal Scientist, Immunosafety, Roche, Ercole Rao, Group Leader, Large Molecules Research - Engineered Protein Therapies, Sanofi, Sarah Leonard, Vice President, Pre-Clinical Development, T-Cypher Bio, Harald Kolmar, Head of Department Applied Biochemistry, Technical University of Darmstadt, Shirley Peters, Director of Antibody Engineering, UCB, Arne Scheu, Co-Founder and CEO, Valink Therapeutics, Paul Moore, Chief Scientific Officer, Zymeworks

Category: Conferences | Science, Health and Medicine | Oncology

Date and Time: 7th July 2026 at 8:00 am to 9th July 2026 at 4:00 pm